As per MRFR analysis, the China Biologics Market Size was estimated at 39.76 (USD Billion) in 2023. The China Biologics Market Industry is expected to grow from 46.22(USD Billion) in 2024 to 376.0 (USD Billion) by 2035. The China Biologics Market CAGR (growth rate) is expected to be around 20.993% during the forecast period (2025 - 2035).
A variety of factors contribute to the growth of the China biologics market which, in turn, gives life to new opportunities for business. One of the major factors driving this market is a growth in chronic conditions, which in turn increases the need for cost-effective solutions. The further investment made by the Chinese government towards biotechnology expansion also plays a role. In addition, the ever-evolving technologies in biomanufacturing and biopharmaceuticals are shifting the attention of companies toward biologic innovation. Government incentives in research and development, together with simplified drug approval policies, make the market more attractive.
There is undoubtedly a gap in the Chinese market when it comes to biologics, and it can be filled by focusing on the demand for biosimilars and personalized medicine. A high incidence of tumors and diabetes due to an older population increases the volume of patients who can take advantage of biological therapies. The growing attention to orphan diseases might enable specialized biotech companies to craft specific non-specific therapies. In addition, collaboration with foreign biopharmaceutical companies can help strengthen the domestic ones, which will improve the country's efficiency in biologics manufacturing. Recently, sizable projects aimed at constructing and equipping biologics manufacturing and research centers have appeared.
Local businesses are improving their production capacity in order to satisfy local and global needs. The amalgamation of supportive government policies, increasing healthcare demands, and the advancements in the biopharmaceutical industry underscore the broad changes taking place in China’s biologics market.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The China Biologics Market Industry is experiencing accelerated demand for advanced biologics due to a significant rise in chronic diseases and an aging population. According to the National Health Commission of China, the country's elderly population is projected to reach 487 million by 2050, with chronic diseases accounting for over 85% of total health expenditures. This growing demographic trend is pushing healthcare providers to invest in effective biologic therapies that cater to age-related ailments.Notably, organizations like the China National Pharmaceutical Group (Sinopharm) are already launching biologic products designed to target chronic conditions, thereby further promoting market growth in the biologics sector. The increased focus on discovering and manufacturing biologics that meet the needs of this demographic shift suggests a promising forecast for the China Biologics Market, bolstered by both public health policies and private sector innovations.
The China government has been actively promoting the development of the biopharmaceutical sector through various policies and subsidies, which has majorly stimulated the China Biologics Market Industry. The State Council of China released a plan aimed at significantly enhancing biotechnology by 2020, which emphasizes innovation, quality control, and a robust regulatory framework. Pharmaceutical companies like GSK, which have been investing in biologics manufacturing in China, stand to benefit from this supportive regulatory environment.According to the China Food and Drug Administration, the approval for new biologic drugs has decreased significantly from an average of 300 days to approximately 90 days, thereby catalyzing innovation and speeding up the delivery of new treatments to market. This favorable policy landscape not only promotes local Chinese firms but also attracts global pharmaceutical companies to invest in the region.
There has been a surge in investment in biotechnological research and development (R) within China, significantly impacting the China Biologics Market Industry. The Ministry of Science and Technology of the People's Republic of China reported a 40% increase in annual R spending in biotechnology sectors over the past five years, reaching approximately 15 billion USD in 2022. Established men like innovator-drug companies and universities are collaborating on groundbreaking research, resulting in a growing pipeline of biologics intended to meet emerging medical needs.Furthermore, local pharmaceutical giants like WuXi AppTec have also stated their commitment to investing in advanced biomanufacturing technologies. This influx of R funding is vital for accelerating innovation and improving the competitiveness of biologics developed in China.
The increasing prevalence of genetic disorders and rare diseases is a crucial driver for the China Biologics Market Industry. Reports from the National Health Commission indicate that around 17 million people in China are currently living with genetic disorders, a figure that has steadily increased over the years. The growing awareness of these conditions has led to an upsurge in demand for targeted biologic therapies, particularly in oncology and rare disease sectors.Organizations like the Chinese Society of Genetics are enhancing their efforts to create awareness and promote research in this field, thereby facilitating the development of innovative biologics targeting specific genetic conditions. This persistent growth in diagnosed cases is creating a sustainable market for biologics that provide new treatment options and personalized medicine, ultimately enhancing the healthcare landscape in China.
The China Biologics Market has shown notable potential, particularly within the Product Service segment, which encompasses various key offerings crucial for advancements in healthcare and therapeutics. This segment stands out due to its multifaceted nature, contributing to innovations across a range of applications. Among these, Monoclonal Antibodies are essential for targeted therapies, often leading the charge in treatments for chronic conditions such as cancers and autoimmune disorders. Their specialized design allows for precision treatment, which is increasingly valued in the evolving healthcare landscape of China. Interleukins represent another vital facet of this segment, playing critical roles in immune responses and clinical settings, particularly in the treatment of systemic inflammatory diseases.
This ongoing focus underscores their significance in the biopharmaceutical arena.Vaccines hold a paramount position as a preventive measure and public health strategy, with China actively increasing its vaccine production capacity. This initiative aligns with the government's commitment to enhance national health security and respond favorably to emerging health challenges. Consequently, vaccines perpetuate their importance, particularly in the context of infectious disease management. Growth Factors further emphasize the relevance of the Product Service segment, given their role in cell growth and proliferation, significantly influencing regenerative medicine and tissue repair therapies.
Gene Therapy has surged in importance as a novel approach to treating genetic disorders, harnessing the potential of biologics to alter disease trajectories fundamentally. This innovation reflects a broader trend toward personalized medicine tailored to individual patient profiles, fostering further interest in advanced therapeutics within the region. Additionally, the "Others" category encapsulates various emerging therapies, reflecting the diverse landscape of solutions developed to address unmet medical needs.
As the industry landscape continues to evolve in China, the demand for advanced biologics is building momentum against a backdrop of supportive government policies, an expanding healthcare infrastructure, and increasing investment in biopharmaceutical research and development. Overall, the Product Service segment represents a dynamic and pivotal part of the China Biologics Market, impacted by rapid advancements in technology and emerging health priorities, underscoring the continuous drive for innovative solutions in the nation's healthcare ecosystem.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The China Biologics Market, categorized by Disease Indication, is witnessing notable growth driven by an increasing prevalence of chronic diseases. Conditions such as rheumatoid arthritis and psoriasis/psoriatic arthritis have garnered significant attention due to the rising number of affected individuals in the region, highlighting the need for effective biological treatments. Cancer remains a leading health concern in China, with innovations in biologics contributing to advanced therapeutic options enhancing patient outcomes. Diabetes presents another major challenge, especially with the growing obesity rates, prompting demands for targeted biologic therapies that address underlying metabolic issues.Other therapeutic areas within this market explore various autoimmune and genetic disorders.
The expansion of the biosimilar pipeline also offers substantial opportunities within these indications, enhancing affordability and accessibility to biologic treatments. Such trends are supported by favorable government policies aimed at promoting biological drug development and reducing healthcare costs, positioning the China Biologics Market for persistent growth while addressing the diverse healthcare needs of its population. The landscape is set to evolve further as research continues to focus on personalized medicine and improved therapeutics, ensuring comprehensive care for patients across different disease indications.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The China Biologics Market is rapidly evolving, reflecting significant advancements in biotechnology and healthcare. The competitive landscape of this market is characterized by the presence of both local and international players, each striving to innovate and gain a competitive edge. With an increasing demand for biologics driven by growing healthcare needs, the market is witnessing heightened activity around research and development, regulatory approval, and commercialization of biologic products, including monoclonal antibodies, vaccines, and recombinant proteins. The competitive insights suggest that companies are focusing on strategic collaborations, enhancing production capabilities, and expanding their geographical presence to strengthen their market position and meet consumer demand.Innovent Biologics has established itself as a formidable presence within the China Biologics Market through its targeted approach to research and development.
The company has successfully developed a range of novel monoclonal antibodies that address complex diseases, which has significantly bolstered its reputation as an innovative leader in the field. Innovent Biologics heavily invests in its pipeline, collaborating with various research institutions and leveraging advanced technologies to enhance drug development. Its commitment to quality and efficiency has resulted in robust manufacturing capabilities, ensuring that it meets both domestic and international standards. Furthermore, the company's strategic partnerships and collaborations with leading pharmaceutical companies exemplify its strengths in enhancing product offerings and accelerating market entry.
Shanghai Jahwa United boasts a considerable footprint in the China Biologics Market, focusing on both the development and manufacturing of biologics and traditional Chinese medicine products. The company’s commitment to innovation is reflected in its broad range of offerings, which include biologics for oncology and autoimmune diseases. Shanghai Jahwa United has been proactive in enhancing its presence through targeted mergers and acquisitions that bolster its research capabilities and product portfolios. The company has established substantial manufacturing facilities and also emphasizes quality assurance, positioning itself favorably in a highly competitive market. Its ability to seamlessly integrate traditional and modern medical practices enables Shanghai Jahwa United to cater to a diverse patient population while contributing to healthier societal outcomes in China.
Recent developments in the China Biologics Market highlight significant advancements and shifting dynamics among key players. Innovent Biologics has seen continuous growth, reflecting increased demand for its innovative cancer therapies. As of September 2023, Shanghai Pharmaceuticals Holding announced a strategic collaboration with Jiangsu Hengrui Medicine to enhance biopharmaceutical research capabilities, marking a noteworthy partnership aimed at expanding its product offerings. Meanwhile, CanSino Biologics is focusing on the development of new vaccines, with recent trials indicating positive outcomes for its COVID-19 vaccine candidates, further asserting its position in the market.
In terms of mergers and acquisitions, Shanghai Jahwa United is reportedly pursuing a potential acquisition of a local biopharmaceutical company to strengthen its portfolio. The valuation of companies, particularly Wuxi Biologics and Sino Biopharmaceutical, has seen substantial growth following recent project announcements that emphasize biosimilar developments. A significant trend observed over the last few years, particularly from 2021 to 2023, reveals a heightened interest in biologics driven by an aging population and a rise in chronic diseases, further stimulating investments across the biopharmaceutical landscape in China.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 39.76(USD Billion) |
| MARKET SIZE 2024 | 46.22(USD Billion) |
| MARKET SIZE 2035 | 376.0(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 20.993% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Innovent Biologics, Shanghai Jahwa United, Qilu Pharmaceutical, China National Pharmaceutical Group, Shanghai Pharmaceuticals Holding, Zhejiang Huahai Pharmaceutical, Wuxi Biologics, Sino Biopharmaceutical, CanSino Biologics, Jiangsu Hengrui Medicine, Kanglongda Medical, Hualan Biological Engineering, Guangzhou Pharmaceutical Holdings, Beijing Wantai Biological Pharmacy Enterprise, Henan Tiankang Pharmaceutical |
| SEGMENTS COVERED | Product Service, Disease Indication |
| KEY MARKET OPPORTUNITIES | Growing demand for biologic therapies, Increasing investment in R&D, Expansion of biosimilars market, Aging population driving healthcare needs, Enhanced regulatory support for biopharma innovations |
| KEY MARKET DYNAMICS | increasing aging population, rising chronic diseases, government investments, advancing biotechnological innovations, regulatory reforms |
| COUNTRIES COVERED | China |
Frequently Asked Questions (FAQ) :
The China Biologics Market is expected to be valued at 46.22 USD billion in 2024.
The expected CAGR for the China Biologics Market from 2025 to 2035 is 20.993%.
The overall market is projected to reach 376.0 USD billion by the year 2035.
The market includes segments such as Monoclonal Antibodies, Interleukins, Vaccines, Growth Factors, and Gene Therapy.
Monoclonal Antibodies are valued at 15.0 USD billion in 2024.
The Interlukin segment is projected to reach 55.0 USD billion by 2035.
Key players include Innovent Biologics, Qilu Pharmaceutical, and CanSino Biologics among others.
The Vaccines segment is expected to be valued at 10.0 USD billion in 2024.
Growing demand for innovative therapies and advancements in biotechnology present significant opportunities in this market.
Challenges include regulatory hurdles and competition from established pharmaceutical companies.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
